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Abstract
Spinal-generated movement disorders (SGMDs) include spinal segmental myoclonus, propriospinal myoclonus,
orthostatic tremor, secondary paroxysmal dyskinesias, stiff person syndrome and its variants, movements in brain
death, and painful legs-moving toes syndrome. In this paper, we review the relevant anatomy and physiology of
SGMDs, characterize and demonstrate their clinical features, and present a practical approach to the diagnosis and
management of these unusual disorders.
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Introduction
Spinal-generated movement disorders (SGMDs) refers to
those movement disorders that originate from the spinal
cord, or in which the spinal cord plays an important role.
SGMDs are central in origin, although in some SGMDs
(such as painful legs-moving toes syndrome (PLMT) or
orthostatic tremor (OT)), both peripheral and supraspinal
mechanisms are also likely involved. We chose to high-
light SGMDs in this review because they are unusual, and
by considering them as a group we may highlight similar
approaches to evaluation and treatment [1]. Before dis-
cussing SGMDs, we will review the relevant anatomy of
the spinal cord.
Review
Spinal cord anatomy and physiology
Afferent signals are conveyed from the axons of dorsal
root ganglia to the spinal cord gray matter. Efferent sig-
nals originate in the anterior (ventral) horn cells or
alpha-motor neurons. Relay circuits may be monosynap-
tic (such as the muscle stretch reflex), or polysynaptic,
(such as the flexion-withdrawal reflex). In the muscle
stretch reflex, the afferent signal comes from the muscle
spindle via Ia afferent fibers, and an efferent signal is
conveyed to the corresponding extrafusal muscle fiber,
leading to muscle contraction (Fig. 1a). Ia afferent fibers
also convey signals to Ia inhibitory interneurons to inhibit
the antagonist muscle, a phenomenon called reciprocal in-
hibition (Fig. 1a). The Renshaw cell, another type of spinal
interneuron, functions in the feedback system by receiving
the signal from the collateral axons of the alpha-motor
neuron and sending an inhibitory signal to the same alpha-
motor neuron and Ia inhibitory interneuron (Fig. 1b).
The second major reflex loop is the flexion-withdrawal
reflex. Cutaneous nociceptive receptors send afferent sig-
nals via Aδ fibers which synapse with multiple interneu-
rons before finally synapsing with the alpha-motor neuron
(Fig. 1c). The final output is excitation and inhibition (re-
spectively) of the ipsilateral flexor and extensor muscles,
and vice versa on the contralateral side. The end result is
an ipsilateral limb withdrawal from the nociceptive stim-
uli, while the opposite limb prepares for support. In an-
other reflex loop, Golgi tendon organs via Ib afferent
fibers, along with joint and cutaneous receptors, convey
signals to Ib inhibitory interneurons (not shown).
Spinal interneurons receive supraspinal descending in-
fluences from the motor cortex, brainstem and cerebellum
via descending pathways (including corticospinal and
rubrospinal pathways), helping to integrate and modulate
movement. The principal neurotransmitters of spinal in-
terneurons are gamma-aminobutyric acid (GABA) and
glycine. When spinal inhibitory interneuron activity is re-
duced, for example due to impaired supraspinal control,
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alpha-motor neurons become hyperexcitable leading to
abnormal involuntary movements.
Control of locomotion is extremely complex, and a
full discussion of spinal control of gait is beyond the
scope of this manuscript. We only briefly touch on several
relevant mechanisms. The locomotor stepping pattern,
the complex sequence of activation of flexor and extensor
muscles required for walking, is controlled by the spinal
locomotor system. In humans, both afferent sensory sig-
nals from peripheral receptors and central pattern genera-
tors (groups of neurons within the spinal cord that can
generate rhythmic motor activities without sensory
Fig. 1 Major spinal reflexes include muscle stretch and cutaneous reflexes. a. The muscle stretch reflex. The afferent signal of the muscle stretch
reflex from the muscle spindle is conveyed via Ia afferent fibers which are axons of dorsal root ganglia. The proximal axons then synapse directly
with the alpha-motor neuron (a monosynaptic reflex), which in turn conveys an efferent signal to the corresponding extrafusal fibers of the agonist muscle
leading to muscle contraction. Ia afferent fibers also synapse with Ia inhibitory interneurons, which in turn convey inhibitory signals to antagonist muscles,
(reciprocal inhibition). b. The feedback control of the muscle stretch reflex. The Renshaw cell is the specialized inhibitory interneuron that
functions in feedback control of the alpha-motor neurons in A. It receives input from collateral axons of the alpha-motor neuron controlling agonist
muscles, and sends inhibitory signals back to the same alpha-motor neuron and also inhibitory signals to the alpha-motor neuron controlling antagonist
muscles. The alpha-motor neurons, inhibitory interneurons and Renshaw cells also receive supraspinal control via descending tracts such as corticospinal or
rubrospinal pathways. c. The cutaneous or flexion-withdrawal reflex. The cutaneous or flexion-withdrawal reflex is a polysynaptic reflex.
Cutaneous nociceptive receptors send afferent signals via Aδ fibers which synapse with multiple interneurons before finally synapsing with
the alpha-motor neuron. The interneurons connect the afferent and efferent signals, resulting in an excitatory signal to the ipsilateral flexor and contralateral
extensor muscles, and an inhibitory signal to the ipsilateral extensor and contralateral flexor muscles. By this mechanism, flexion of the ipsilateral agonist
muscle withdraws the limb from the nociceptive stimuli. An opposite chain is reversed in the opposite limb to prepare for support
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afferent input [2, 3]), play an important role in locomo-
tion. Supraspinal control from the mesencephalic loco-
motor region and the cerebellum also modulates the
spinal locomotor system. Propriospinal pathways ascend
and descend along the long axis of the spinal cord to
interconnect short and long segments. Their presence and
role in humans has not yet been proven, but likely they
help to coordinate forelimb and hindlimb movements
during locomotion in quadrupeds [4].
Knowledge of spinal cord physiology is useful in under-
standing the pathophysiology of SGMDs. For example,
dysfunction of inhibitory interneurons leads to spinal seg-
mental myoclonus. In stiff person syndrome, reduced input
of inhibitory neurons via supraspinal control has been im-
plicated. Automatic stepping patterns in near-brain death
may occur due to disconnection of supraspinal control,
allowing the central pattern generators to fire uninhibited.
A summary of lesions and their location responsible for
SGMDs is discussed further in the text below and illus-
trated in Fig. 2.
General considerations
If the clinician suspects that the spinal cord is a possible
generator of involuntary movements (i.e., anatomically
localizes the movements based on the distribution), phe-
nomenology (i.e., classifying the movements based on
their characters) may be useful in diagnosis. When myo-
clonic jerks are present, spinal segmental myoclonus
(SSM), propriospinal myoclonus (PSM), and progressive
encephalomyelitis with rigidity and myoclonus (PERM)
should be considered. Orthostatic tremor (OT) is an ex-
ample of a SGMD with tremor. Dystonic posturing is a
phenomenon in secondary paroxysmal dyskinesias, in-
cluding paroxysmal tonic spasms in multiple sclerosis
(MS). SGMDs with stiffness include stiff person syn-
drome (SPS) and its variants, stiff limb syndrome (SLS)
Fig. 2 Localization in SGMDs. The figure illustrates the anatomical localization from the spinal cord, including the spinal reflex loop with inhibitory
interneurons. The propriospinal pathway is shown on the opposite side. The interneurons and alpha-motor neuron also receives supraspinal control via the
descending tracts. Higher levels of control including brainstem and thalamus are also depicted. The table demonstrates the location(s) that
is(are) responsible for the pathophysiology in each SGMD. The location is classified as 1) the spinal cord including spinal interneurons, spinal reflex loops
and other spinal locations, and 2) supraspinal control including descending tracts (part of which is also located in the spinal cord), brainstem and others
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and PERM. Movements in brain death are often stereo-
typed, similar to primitive spinal reflexes or stepping
patterns.
Certain examination findings may also help guide the
diagnosis. One common pattern in SGMDs is involve-
ment of one or multiple limbs without axial or bulbar
involvement. Monocrural involvement occurs in SSM,
SLS, and PLMT. Less commonly these disorders may
affect two limbs. Almost all SGMDs lack bulbar or cra-
nial involvement with few exceptions such as PERM,
some cases of paroxysmal tonic movements in MS and
undulating facial movements in brain death. Most
SGMDs are typically hyperkinetic: myoclonus, tremor,
dystonia, spinal reflexes or locomotor stepping move-
ments all involve excess movements. Stiffness syn-
dromes such as SPS or SLS may appear hypokinetic,
but are better classified as sustained hyperkinetic
spasms.
We next review the main clinical features, pathophysi-
ology, and treatment of each SGMD (see Table 1 for sum-
mary). While treatment of SGMDs may include multiple
modalities, pharmacotherapy of each SGMD is summa-
rized in Table 2.
Spinal segmental myoclonus (SSM)
SSM originates from one or a few adjacent segments of
the spinal cord. Loss of inhibition of spinal interneurons
leads to hyperexcitation of anterior horn cells [5]. SSM
is typically rhythmic or semi-rhythmic, approximately
1–2 Hz in frequency, usually stimulus-insensitive [6],
and involves one (or less commonly two) limbs or trun-
cal/abdominal muscles (Additional file 1: Video segment
1). While there is no systematic study in the literature
on the frequency of SSM among different spinal seg-
ments or myotomes, the involved body part(s) is(are)
likely correlated with the anatomical location of the le-
sion(s) within the spinal cord. Differentiating SSM from
myoclonus originating from the periphery (nerve roots,
plexus or peripheral nerves) may be challenging. One im-
portant clue is that in peripherally-generated myoclonus,
the distribution of muscles involved corresponds to the
nerve roots [7, 8], plexus [9] or peripheral nerves [10–13],
whereas SSM typically involves multiple muscles inner-
vated by one to three adjacent spinal levels and can be
bilateral. In SSM patients it is critical to exclude struc-
tural lesions of the spinal cord such as vascular, inflam-
matory [14, 15], infectious [16, 17], postinfectious [18],
demyelinating [19], degenerative [20, 21], paraneoplas-
tic [22], and space-occupying lesions [23, 24] with con-
trast MRI imaging. Specific treatment addresses the
underlying etiology if one is found, while symptomatic
treatments include clonazepam [21, 25, 26], valproic
acid [26] and levetiracetam [27].
Propriospinal myoclonus (PSM)
PSM may originate from the propriospinal pathways, which
are classically distinguished by their relatively slow conduc-
tion in contrast to the faster-conducting corticospinal path-
ways. However, the presence and role of propriospinal
pathways in humans has not yet been confirmed. Axial
musculature is purely or predominantly involved in PSM,
and patients typically have slow flexion truncal jerks that
may be stimulus-sensitive (for example in response to tact-
ile stimuli) (Additional file 1: Video segment 1). The latency
between the examiner eliciting the stimulus and the pa-
tient’s movement is noticeably longer than in cortical myo-
clonus. This delay in onset of a truncal jerk after eliciting a
reflex can be very helpful in the office evaluation of these
patients, as demonstrated in Additional file 1: Video seg-
ment 1. Electrophysiology typically reveals recruitment or
simultaneous spread of ascending and descending segments
from a thoracic spinal source. PSM may be idiopathic or
may be associated with spinal cord lesions. Some authors
considered propriospinal myoclonus to be a functional
disorder, due to the finding of Bereitschaftspotential or pre-
movement potentials in some PSM patients [28–32]. Dis-
tinguishing between organic and psychogenic PSM based
on clinical grounds alone may not be reliable, and there is
thus a role of electrophysiologic study [28, 29, 32]. How-
ever, a recent study found true microstructural defects such
as disruption of fiber tracts in the spinal cord using diffu-
sion tensor imaging [33]. Our personal view, supported by
van der Salm et al. [28], is that not all PSM cases are psy-
chogenic: there are both organic and psychogenic forms.
Given similar clinical features among patients and that sev-
eral movement disorders such as dystonia was, in history,
incorrectly envisioned as a psychogenic disorder due to in-
adequate knowledge in pathophysiology, the strong conclu-
sion on psychogenicity to the whole group of PSM patients
has to be made with caution.
Orthostatic tremor (OT)
OT is a very fine fast tremor, felt in the legs when a pa-
tient stands, classically disappearing when the patient
walks [34]. Patients typically complain of unsteadiness,
and if symptoms have been present for a prolonged
period they may complain of inability to walk or gait
fearfulness (Additional file 2: Video segment 2). The os-
cillations may be audible when a stethoscope is placed
behind the knee, producing a characteristic sound (“the
helicopter sign”) [35]. OT is one of the highest frequency
tremors, (13–18 Hz) [36, 37], and tremor may be invis-
ible on exam [38, 39] but is usually palpable. In patients
with no visible tremor, the diagnosis can generally be
made by the history and examination illustrating inabil-
ity to stand or unsteadiness while standing with im-
provement or no difficulty when walking. Tremor may
also involve axial musculature or even the arms in the
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Table 1 Summary of phenomenology, pathophysiology, main clinical features, investigations and treatment of spinal-generated movement disorders (SGMDs)
SGMDs Phenomenology Pathophysiology Main clinical features Investigations Treatment
Spinal segmental
myoclonus (SSM)
Myoclonus • Loss of inhibition of spinal
interneurons→ hyperexcitation
of anterior horn cells
• Jerks of 1 or 2 limbs
• Rhythmic or semi-rhythmic
• Generally not stimulus-sensitive
• MRI of the spinal cord • Rx of specific
etiologies.




Myoclonus • Possible defects in propriospinal
pathways (not yet proven in humans)
• Psychogenic etiology also proposed
• Slow truncal jerking
• Flexion more common than extension
• Stimulus-sensitive, but longer latency than
cortical myoclonus
• MRI of the spinal cord
• EP testing
• Rx of specific
etiologies in 2°
forms





• Proposed tremor generators:
brainstem, thalamus, and spinal cord
• 1° and 2° (OT-plus) forms exist
• 13–18 Hz; in legs and trunk
• Present when standing but not walking
• Subjective unsteadiness; tremor may not
be visible




• MRI of the brain or spinal cord
(if exam is abnormal and 2°
OT is suspected)
• Mainly CLZ or GBP
• L-dopa or DA may









Dystonia • Ephaptic transmission between
partially-demyelinated axons anywhere
in central nervous system
• Common locations: contralateral cerebral
peduncle, internal capsule, and spinal cord
• Painful; involves unilateral arm or leg
• Typically non-kinesigenic
• Last several seconds to minutes
• May involve ipsilateral face
• Aggravated by hyperventilation
• Can be initial presentation of MS
• MRI of the brain and spinal cord
• Other MS/NMOSD work-up
including CSF studies
• CBZ or acetazolamide
Stiff person syndrome
(SPS) and its variants
Stiffness • Impaired spinal GABAergic and glycinergic
inhibitory circuits → CMUA
• Supraspinal mechanisms proposed
• Classic form: stiffness of the trunk and legs,
hyperlordotic gait
• Stiff limb variant: involves only 1–2 limbs
• Ab testing (serum anti-GAD,
anti-amphiphysin; less commonly
anti-glycine or GABAA receptor)
• Malignancy work-up
• Rx of specific
etiology if any
• Immunosuppressive
Rx: steroid, IVIg, and/
or PLEX; chronic oral
agents such as MMF,
AZA and CYC









• Loss of spinal inhibitory interneurons
• Brainstem also involved
• Myoclonic jerks of the trunk, limbs and
cranial muscles
• +/− Nystagmus, oculomotor abnormalities,
dysarthria and dysphagia
• Ab testing (serum and CSF anti-GAD,
anti-glycine receptor, anti-DPPX)
• MRI of the spinal cord and brainstem
• CSF studies may be required
• Rx of specific etiology
if any
• Immunosuppressive




Spinal reflexes • Disconnection of supraspinal control →
disinhibition of the spinal reflexes
• Some proposed released phylogenetically
primitive patterns
• Automatic stepping: spinal
automatism from spinal CPG
• 2 types (examples shown)
- Automatisms (abdominal contraction,
undulating toe movements)
- Reflexes (after neck flexion, finger pinching
or testing Babinski sign)
• Automatic stepping reported in a near
brain-dead patient
• Confirmation of brain death (physical




















• Proposed mechanism: peripheral nerve
pathology→ 2° impairment in spinal and/
or supraspinal controls, and central
sensitization
• Slow 1–2 Hz, athetoid-like
• Involves fingers or toes
• Moves in vertical and/or horizontal planes
• Pain usually the most debilitating symptom
• Painless form present
• Work-up for associated neuropathies
or radiculopathies depending on
clinical context
• MRI of the spinal cord rarely
required
• Rx of concomitant
diseases such as
neuropathies
• GBP or PGB





Summary table of pathophysiology, clinical features, investigations and treatment of SGMDs
*Movements in brain death and automatic stepping are normal findings, not "disorders".
Abbreviations: MRI magnetic resonance imaging, Rx treatment, CLZ clonazepam, VPA valproate, LVT levetiracetam, EP electrophysiologic,1° primary, 2° secondary, GBP gabapentin, L-dopa levodopa, DA dopamine
agonist, CBZ carbamazepine, CSF cerebrospinal fluid, GABA gamma-aminobutyric acid, CMUA continuous motor unit activity, Ab antibody, GAD glutamic acid decarboxylase, IVIg intravenous immunoglobulin, PLEX
plasma exchange, MMF mycophenolate mofetil, AZA azathioprine, CYC cyclophosphamide, BZD benzodiazepine, CPG spinal central pattern generator, TCD transcranial Doppler ultrasound, PGB pregabalin, TCA tricyclic















weight-bearing position [40]. Interestingly, tremor may be
immediately attenuated by lightly touching objects such as
a table, a wall, or the examiner’s hand (Additional file 2:
Video segment 2). An important differential in OT is
orthostatic myoclonus (OM), usually distinguished by
electrophysiology [41, 42].
OT may be primary/idiopathic or secondary (or OT-
plus), the later accompanying pontine [43], spinal [44],
cerebellar [45], or parkinsonian pathology [46]. Two cases
of OT with concomitant hydrocephalus in the setting of
aqueductal stenosis and chronic relapsing polyradiculo-
neuropathy have been reported [47]. Investigations such
as neuroimaging of the brain or spinal cord in OT patients
are not mandated unless other neurologic signs are
present. OT is typically treated with clonazepam or gaba-
pentin [48], and response to treatment can occasionally be
dramatic (Additional file 2: Video segment 2). Dopamine
agonists or levodopa may be useful, especially in cases
with concomitant parkinsonism [46, 49]. Other medica-
tions such as propranolol, primidone, phenytoin, carba-
mazepine and levetiracetam have been used, with variable
success [46, 50]. Possible sources of the generator in OT
include supraspinal structures such as the brainstem
[51, 52], thalamus [53], spinal cord [52, 54] and cerebel-
lum [55]. However, the emergence of OT after spinal
cord lesions [54], and the benefit of spinal cord stimu-
lation in medically-refractory OT [56] support a pos-
sible spinal etiology.
As a mimicker of OT, OM will be discussed briefly here.
Patients with OM usually present with gait unsteadiness
and a complaint of leg shaking or jerking [41, 42]. Diffi-
culty initiating gait or “gait apraxia” is often found [41, 42].
Due to these symptoms, patients may be misdiagnosed as
normal pressure hydrocephalus or OT [42]. Over 50–70 %
of OM patients in two studies had associated
neurodegenerative diseases including Parkinson’s disease,
dementia with Lewy bodies, multiple system atrophy and
Alzheimer’s disease [41, 42]. In addition to OT, it is
thought to be one of under-recognized causes of unsteadi-
ness [57, 58], and the diagnosis is confirmed by electro-
physiologic study demonstrating myoclonus. Treatments
that have been used in OM include clonazepam [42] and
levetiracetam with variable results [42, 57]. However, the
strong evidence is still lacking due to a small number of
patients and short follow up duration.
Secondary paroxysmal dyskinesias, including paroxysmal
tonic spasms in multiple sclerosis (MS) and neuromyelitis
optica spectrum disorders (NMOSD)
Secondary paroxysmal dyskinesias may involve the spinal
cord. Important clues that a paroxysmal dyskinesia is sec-
ondary rather than primary include the presence of signifi-
cant pain [59] and an abnormal interictal examination.
Secondary paroxysmal dyskinesias may occur in hypo-
parathyroidism [60], pseudohypoparathyroidism [61, 62],
supraspinal lesions [59, 63], spinal cord glioma [64] and
spinal cord compression [65, 66].
Paroxysmal tonic spasms in MS, also called paroxysmal
dystonia or secondary dyskinesias, are one of the most
common causes of secondary paroxysmal dyskinesias.
Painful dystonic spasms usually involve an ipsilateral arm
and/or leg or face in some cases, without kinesigenic trig-
ger, lasting several seconds to minutes [67, 68]. Episodes
are often aggravated by hyperventilation, likely due to re-
spiratory alkalosis and increased ephaptic transmission be-
tween partially demyelinated axons [69]. Paroxysmal tonic
spasms can occur as the initial presentation of MS [70],
but are usually seen once the disease is well established. It
is important to remember that paroxysmal spasms of MS
are not diagnostic of a spinal cord locus, and they may
Table 2 Pharmacological treatment of each spinal-generated movement disorder
SGMDs CLZ VPA LVT CBZ GBP ImRxa Others
Spinal segmental myoclonus (SSM) + + +
Propriospinal myoclonus (PSM) + +
Orthostatic tremor (OT) + + +b
Paroxysmal tonic spasms in multiple sclerosis (MS) + +c
Stiff person syndrome (SPS) and its variants +/−d + +e
Progressive encephalomyelitis with rigidity and myoclonus (a variant of SPS) +/−d + +e
Painful legs-moving toes syndrome (PLMT) +f +f + +g
Pharmacologic therapies in SGMDs. The effective or possibly effective therapies are indicated by “+”. Drugs utilized in SGMDs are mostly antiepileptics (including
benzodiazepines, especially clonazepam, valproate, levetiracetam, carbamazepine, and gabapentin), and immunotherapiesa (including steroids, intravenous
immunoglobulin, and/or plasma exchange, as well as immunosuppressants such as azathioprine, cyclophosphamide and mycophenolate mofetil)
Abbreviations: SGMDs spinal-generated movement disorders, CLZ clonazepam, VPA valproate, LVT levetiracetam, CBZ carbamazepine, GBP gabapentin,
ImRx immunotherapies
bDopaminergic therapies including dopamine agonists and levodopa in case with co-existing parkinsonism
cAcetazolamide
dClonazepam may be used, but anecdotally is less effective than diazepam
eBenzodiazepines, especially diazepam
fIn our experience, these medications are used less often than gabapentin
gPregabalin is also used. Other medications reported in small number of patients include baclofen, carbamazepine, and tricyclic antidepressants
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also originate in the contralateral cerebral peduncle [71],
thalamus [72, 73], or internal capsule [71, 74, 75]. Paroxys-
mal tonic spasms often behave independently of MS; they
can remit in spite of progression of MS or vice versa, and
an EEG may be required to rule out seizures or epilepsia
partialis continua [76, 77]. Paroxysmal tonic spasms are
even more common in NMOSD than in MS [78, 79]. One
recent study in NMOSD found that painful tonic spasms
are more common in aquaporin-4 (AQP-4) antibody-
positive than myelin oligodendrocyte glycoprotein (MOG)
antibody-positive cases [80].
The pathophysiology of paroxysmal tonic spasms in MS
or NMOSD remains unclear. Osterman and Westerberg
proposed that ephaptic transmission between demyelinated
axons [67] might be responsible. Alteration in supraspinal
control might lead to a reduction in inhibitory spinal
interneuron output, resulting in hyperexcitation of the
alpha-motor neuron. Paroxysmal tonic spasms in MS
or NMOSD are typically treated with low-dose carba-
mazepine [67, 81] or acetazolamide [74, 82]. Gabapen-
tin has also been reported to be effective [83].
Stiff person syndrome (SPS) and stiff limb syndrome
(SLS)
Classic SPS is characterized by stiffness of the trunk and
limb muscles. Axial musculature is usually involved, produ-
cing a classic hyperlordotic, dromedary gait. Stiff limb syn-
drome (SLS) is a rare form of SPS in which one limb is
involved (Additional file 1: Video segment 1). SPS affects
women disproportionately [84]. The electrophysiologic hall-
mark of SPS and SLS is continuous motor unit activity
(CMUA) that persists even when the patient tries to relax
[85]. High titers of glutamic acid decarboxylase (GAD) anti-
bodies are found in 80 % of SPS [86]. GAD antibodies are
not specific for SPS, as they may also be present in type I
diabetes, autoimmune cerebellar ataxia, and autoimmunue
polyglandular syndrome [87], either with or without SPS.
Amphiphysin antibodies occur less commonly than GAD
antibodies, and when present may signify an underlying
malignancy [88–93]. While GAD and amphiphysin are
proteins in the presynaptic terminal of inhibitory neurons,
other antibodies to proteins at postsynaptic sites (GABAA
and glycine receptors) have also been reported in SPS
[94–96]. Glycine receptor antibodies are not only
associated with progressive encephalomyelitis with
rigidity and myoclonus (PERM), but also classic and
variant SPS, in both GAD antibody-positive and
negative cases [96, 97].
Spinal and supraspinal pathways are important in SPS.
Floeter and colleagues demonstrated abnormalities not
only in spinal GABAergic circuits but also in spinal glyci-
nergic inhibitory circuits [98]. The sensorimotor cortex
[99] and motor and premotor cortices also likely play a
role [100, 101]. Electrophysiologic abnormalities in the
brainstem similar to hyperekplexia have also been demon-
strated in SPS [102].
The diagnosis of SPS and SLS rests on the history, exam,
comfirmation by physiology, and serology. Malignancy
should be excluded, especially in SLS. Immunosuppressive
therapy is the cornerstone of treatment, including
intravenous steroids, IVIg or plasma exchange [91],
although formal evidence-based guidelines regarding
treatment are still lacking. For symptomatic treat-
ment, oral pharmacologic agents include benzodiaze-
pines, especially diazepam, and baclofen [85]. In
cases where symptoms remain poorly controlled,
intrathecal baclofen or spinal cord stimulation may
be considered [103].
Progressive encephalomyelitis with rigidity and myoclonus
(PERM)
PERM is considered to be a variant of SPS (“stiff-person-
plus” syndrome) or a form of brainstem myoclonus
[104]. It has been proposed to originate from the brain-
stem and spinal cord [104], and is thus not a pure SGMD.
However, we include it in this review because of the clin-
ical overlap with SPS and similarity in treatment approach.
In the spinal cord, loss of spinal inhibitory interneurons
leads to excess excitation of alpha-motor neurons, similar
to SPS [105]. PERM was historically termed “spinal neuro-
nitis” due to the finding of degeneration of long descend-
ing motor tracts [104], however cranial involvement and
antibodies to glycine receptors [106] support a brainstem
origin as well.
PERM is often rapidly progressive and typically in-
volves the trunk or lower limbs. Myoclonus is often
present, hence the term “stiff-person-plus” or “jerking
SPS” [107]. Myoclonus typically involves the trunk or
limbs as well as cranial-nerve innervated muscles, and is
frequently stimulus-sensitive. Other brainstem signs
such as nystagmus, oculomotor abnormalities, dysarth-
ria, and dysphagia can be present, as well as cerebellar
ataxia [108, 109], cognitive impairment, encephalopathy
and seizure [106, 110, 111]. Dipeptidyl-peptidase-like
protein-6 (DPPX) [108] and glycine receptor antibodies
[96, 106, 111, 112] may be present, in addition to
the previously mentioned anti-GAD antibodies [113].
The diagnostic work-up in patients with PERM in-
cludes imaging of the brainstem and spinal cord to
rule out structural lesions, cerebrospinal fluid exam
to look for infectious, parainfectious, paraneoplastic
[114, 115] and autoimmune etiologies, as well as
anti-GAD and glycine receptor antibodies in serum
and cerebrospinal fluid. Evidence-based recommen-
dations are lacking, but immunosuppressive therapies
including steroids, IVIg, plasma exchange and others
agents such as mycophenolate mofetil or azathio-
prine have been used. [106, 108, 110, 112].
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Movements in brain death
Movements in brain death are in fact normal findings and
are not rare. They may be classified as automatisms, where
movements occur spontaneously without stimuli, and re-
flexes, where movements occur after stimuli [116]. The la-
tency between onset of brain death and the occurrence of
movements varies from minutes to days [116, 117]. Spittler
and colleagues proposed that this latency could be attrib-
uted to spinal shock. More than 40 types of movements
have been described; most involve the trunk or limbs, how-
ever some involve cranial regions such as facial myokymia,
eyelid opening and tongue myoclonus [118, 119].
Examples of automatisms include tonic arm flexion, ab-
dominal contraction, knee, hip and leg flexion, and undu-
lating toe movements [116, 120]. Reflex movements may
occur after muscle stretch (muscle stretch reflexes), or
stimuli to skin or deeper tissue (cutaneo-muscular re-
flexes). The reflexes can involve only one (monosegmental
reflexes) or multiple segments (oligo- or polysegmental re-
flexes) of the spinal cord. Spittler and colleagues described
31 spinal reflexes [117], including muscle stretch reflexes
of biceps, triceps, brachioradialis, finger flexion after bi-
ceps stretching and cremasteric reflexes. Neck flexion was
reported to trigger movements such as shoulder protru-
sion, abdominal contraction, hip flexion and adduction or
abdominal contraction. Movements following finger
pinching included shoulder protrusion, abdominal con-
traction or arm/finger flexion. Sole stimulation, as in test-
ing for the Babinski sign, led to hip and/or knee flexion or
toe flexion [121]. Perhaps the most dramatic reflex is the
Lazarus sign, in which both elbows and hands flex to-
wards the chin and the patient may appear to arise from
the bed [122, 123]. It can occur spontaneously (automa-
tism) or as a reflex after stimuli such as during apnea test-
ing or neck flexion. It is important for clinicians to
recognize automatisms and reflexes so that the diagnosis
of brain death is not distracted by their presence, and the
patient’s family is appropriately reassured. For video ex-
amples, please refer to McNair and Meador [121], and
Bueri et al. [122].
The movements of brain death are thought to be gen-
erated by the spinal cord. Several mechanisms have been
proposed, including disinhibition of anterior horn cells
disconnected from supraspinal control [116], and release
of more phylogenetically primitive patterns of movement
due to decoupling of the spinal cord from the neocortex
and brainstem [117]. Interestingly, automatic stepping
has been reported in patients prior to the declaration of
brain death when the brainstem was compromised from
central herniation [124]. In cats transected at the rostral
margin of the superior colliculi, animals demonstrated
spontaneous walking. The stepping reflex also occurs in
infants before 6 weeks of age when they are held with
feet placed on a flat surface. Collectively, these
phenomena support the idea of a central pattern gener-
ator for locomotion within the spinal cord that may be
responsible for spinal automatisms when it is discon-
nected from descending inhibitory influences.
Painful legs-moving toes syndrome (PLMT)
Although named PLMT, this syndrome can be painless
or even involve upper extremities, (painless legs-moving
toes or painful arms [or hands]-moving fingers syn-
drome [125, 126]). The movements of toes or fingers are
slow, writhing, typically 1–2 Hz, occurring in vertical
(flexion/extension) and/or horizontal (abduction/adduc-
tion) planes (Additional file 3: Video segment 3). Invol-
untary movements of toes or fingers in a pure horizontal
plane is virtually pathognomonic of the condition. Ini-
tially one limb may be involved, but contralateral spread
can occur [127]. Pain is often the most debilitating fea-
ture of PLMT, and treatments such as gabapentin or
pregabalin may be helpful [128]. Spinal cord stimulation
has been reported to improve the movements [129].
PLMT may occur after nerve root, plexus or peripheral
nerve lesions [127], and less commonly with spinal cord
lesions or compression [127, 130]. The pathophysiology
of PLMT remains unknown. One proposal included per-
ipheral nerve pathology triggering central spinal and/or
supraspinal reorganization [127, 131, 132]. Pain, possibly
attributed to central sensitization, and the complexity of
the involuntary movements support a central rather than
peripheral etiology [127].
PLMT is difficult to treat. Studies or reports have been
conducted on a small scale. It is however important to look
for and treat an underlying peripheral neuropathy. In
addition to gabapentin, pregabalin and spinal cord stimula-
tion as mentioned above, various treatments reported to be
effective include baclofen, carbamazepine [127, 133], ben-
zodiazepines such as clonazepam, tricyclic antidepressants
[134], adenosine [135], sympathetic blockade [127, 136],
epidural block [137], transcutaneous electrical nerve stimu-
lation [138] and botulinum toxin injection [139–141].
Conclusion
SGMDs are a unique group of movement disorders, shar-
ing many features. We hope that our review will help cli-
nicians care for these challenging patients.
Video segments
Video segment 1
Additional file 1: Video segment 1 (https://drive.goo-
gle.com/open?id=0BxN303l61fkBdlVyT2VJU2I1aEE)
demonstrates the phenomenology of spinal segmental
myoclonus, priopriospinal myoclonus (PSM) and stiff limb
syndrome. Patient 1 is a 50-year-old woman with a 3-year
history of spinal segmental myoclonus affecting the lower
back and abdomen. Examination revealed symmetric
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volleys of myoclonic jerks in abdominal muscles, wors-
ened when she lifted her legs against resistance. A rectus
jerk could be elicited by tapping the patellar reflex with
sufficient force, illustrating stimulus-sensitivity, unusual
for this disorder. Patient 2, a 31-year-old woman, devel-
oped spinal segmental myoclonus several weeks after a se-
vere viral upper respiratory infection. Myoclonic jerks of
the thoracic abdominal muscles were rapid and symmet-
ric. Movements interfered with her ability to provide dia-
phragmatic support for speech or sustained vocalization.
Patient 3 demonstrated spinal segmental myoclonus of
the thoracic abdominal muscles, worse on leaning to the
right. The next three patients demonstrate classic phe-
nomenology of PSM. Of note, the diagnosis of PSM in our
patients was made on clincial grounds. The more specific
diagnosis of organic or psychogenic PSM cannot be con-
firmed due to unavailibility of electrophysiologic study.
Patient 4 is a 62-year-old woman who developed pro-
priospinal myoclonus in her upper legs, buttocks and
lower torso. Movements occurred with sitting and lying
down, disappeared on standing, and persisted in sleep (by
report). A charactersitic delay in reflex-induced myoclonic
jerks was evident bilaterally, with both the biceps and knee
jerks. Patient 5 is a 64-year-old woman with a history of
thoracic spine surgery at the T7-8 level, with a 13-year his-
tory of priopriospinal myoclonus. Abdominal jerks co-
alesce in the video to produce continuous abdominal
spasms. Biceps and triceps reflexes trigger a time-delayed
jerk that also flexes the trunk. Patient 6 demonstrates pro-
priospinal myoclonic jerks of the trunk on standing which
were initially dismissed as psychogenic. A characteristic
time-delayed jerk is evident with biceps and patellar re-
flexes. The work up of Patients 1–6 included spinal mag-
netic resonance imaging which was negative for structural
lesions in the spinal cord. Clonazepam, valproic acid and/
or levetiracetam were employed in these patients with
variable improvement (not shown in the video). Patient 7
developed stiffness and cramping of his left leg with walk-
ing. His medical history was notable for juvenile diabetes,
and anti-GAD antibody was markedly positive. Continu-
ous motor unit firing on EMG confirmed the diagnosis of
stiff limb syndrome (SLS). Treatment with intravenous
immunoglobulin and diazepam dramatically improved his
symptoms.
Video segment 2
Additional file 2: Video segment 2 (https://drive.google.-
com/open?id=0BxN303l61fkBYnBMeVFqazNib2s) demon-
strates the rich phenomenology of orthostatic tremor (OT)
in five patients. Patient 1 is an 83-year-old man who pre-
sented with a 10-year history of difficulty standing while
shaving or waiting for a train. Examination revealed OT,
visible and palpable in the legs, as well as sense of imbal-
ance triggered by standing and immediately relieved by
walking. Patient 2 is a 75-year-old woman with a thoracic
arachnoid cyst and a 3-year history of OT. Symptoms were
triggered by standing, relieved by walking, and recurred
even as she briefly stopped to turn. The movements may
be secondary OT. We cannot prove they are the result of
the arachnoid cyst, but they started after the cyst was rec-
ognized. Patient 3, an 86-year-old man with a 1-year history
of significant OT, demonstrates the marked benefit he ob-
tains from peripheral sensory input (gently holding the ex-
aminer’s hand, or touching the wall with his hand). The
video mimics how he uses this sensory input to ambulate
in his home, walking while guiding the palm or even the
dorsum of his hand along the wall. Patient 4, a 76-year-old
woman with a 6-year history of severe OT, had already de-
veloped gait fearfulness by the time of her evaluation.
Examination in the office revealed OT which improved
instantly by grasping the examiner’s hand or even one fin-
ger. She would not allow the examiner to let go of her
hands to stand unassisted. Treatment with clonazepam
0.5 mg twice daily markedly improved her OT, allowing her
to walk unassisted (not shown on video). Patient 5, a 70-
year-old woman with a 3-year history of OT, could no lon-
ger walk without a rolling walker. Examination demon-
strated OT that would occur within 5 seconds of standing
and was relieved by touching the table. Her walking was
impaired although she was able to ambulate with the sen-
sory input of holding one finger of the examiner’s hand.
Treatment with clonazepam 0.5 mg twice daily allowed her
to stand and walk unassisted (demonstrated on video).
Video segment 3
Additional file 3: Video segment 3 (https://drive.google.-
com/open?id=0BxN303l61fkBX0dGWi1WR3gtZGc) dem-
onstrates the phenomenology of painful legs-moving toes
(PLMT) and painful hands-moving fingers (PHMF)
syndromes. Patient 1 presented with a 3-year history
of involuntary movements of the toes, observed even
in deep sleep. Movements were accompanied by pain
that was refractory to medication. Examination re-
vealed bilateral undulating movements of the toes in
both flexion/extension and the lateral plane. Patient 2
presented with involuntary movements of the left toes
which were annoying but not painful. Examination re-
vealed undulating lateral movements of all five toes,
consistent with painless, unilateral PLMT. Patient 3
demonstrates similar movements affecting the fingers
of the left hand, accompanied by pain that persisted
in sleep—PHMF Patient 4, a 53-year-old man with a
20-year history of pain and involuntary movements of
the left hand, demonstrates a similar phenotype of
PHMF. Side to side undulating movements of the
third, fourth and fifth fingers were disabling and re-
fractory to treatment.
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Consent statement
Written informed consent was obtained from the pa-
tients for publication of all video segments. A copy of
the written consent is available for review by the Editor-
in-Chief of this journal.
Additional files
Additional file 1: Video segment 1 demonstrates the phenomenology
of spinal segmental myoclonus, priopriospinal myoclonus (PSM) and
stiff limb syndrome. See section on Video segments for more details.
(MP4 610968 kb)
Additional file 2: Video segment 2 demonstrates the rich
phenomenology of orthostatic tremor (OT) in five patients. See section
on Video segments for more details. (MP4 503870 kb)
Additional file 3: Video segment 3 demonstrates the
phenomenology of painful legs-moving toes (PLMT) and painful
hands-moving fingers (PHMF) syndromes. See section on Video
segments for more details. (MP4 211600 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PT participated in drafting/revising the manuscript. TT participated in
drafting/revising the manuscript, and illustrating all figures. SJF participated
in drafting/revising the manuscript, video editing and study concept. All
authors read and approved the final manuscript.
Acknowledgements
We thank Paul Greene, MD for helpful comments.
Author details
1Department of Neurology, Movement Disorder Division, Icahn School of
Medicine at Mount Sinai, New York, USA. 2Department of Medicine,
Neurology Division, Faculty of Medicine, Siriraj Hospital, Mahidol University,
Bangkok, Thailand. 3Department of Neurology, University Hospitals Case
Medical Center, Cleveland, USA.
Received: 9 September 2015 Accepted: 24 November 2015
References
1. Thiriez C, Gurruchaga JM, Goujon C, Fenelon G, Palfi S. Spinal stimulation for
movement disorders. Neurotherapeutics. 2014;11:543–52.
2. Dietz V. Spinal cord pattern generators for locomotion. Clin Neurophysiol.
2003;114:1379–89.
3. Marder E, Calabrese RL. Principles of rhythmic motor pattern generation.
Physiol Rev. 1996;76:687–717.
4. Juvin L, Simmers J, Morin D. Propriospinal circuitry underlying interlimb coordination
in mammalian quadrupedal locomotion. J Neurosci. 2005;25:6025–35.
5. Di Lazzaro V, Restuccia D, Nardone R, Oliviero A, Profice P, Insola A, et al.
Changes in spinal cord excitability in a patient with rhythmic segmental
myoclonus. J Neurol Neurosurg Psychiatry. 1996;61:641–4.
6. Davis SM, Murray NM, Diengdoh JV, Galea-Debono A, Kocen RS. Stimulus-
sensitive spinal myoclonus. J Neurol Neurosurg Psychiatry. 1981;44:884–8.
7. Seidel G, Vieregge P, Wessel K, Kompf D. Peripheral myoclonus due to
spinal root lesion. Muscle Nerve. 1997;20:1602–3.
8. Sotaniemi KA. Paraspinal myoclonus due to spinal root lesion. J Neurol
Neurosurg Psychiatry. 1985;48:722–3.
9. Banks G, Nielsen VK, Short MP, Kowal CD. Brachial plexus myoclonus.
J Neurol Neurosurg Psychiatry. 1985;48:582–4.
10. Lagueny A, Reboul G, Kien P, Duche B. Myoclonus of the serratus anterior
muscle after posterolateral thoracotomy. Clin Neurol Neurosurg. 2014;122:1–3.
11. Camerota F, Celletti C, Paoloni M, Serrao M, Inghilleri M, Pierelli F, et al.
Myoclonus of the scapula after acute long thoracic nerve lesion: a case
report. Mov Disord. 2006;21:71–3.
12. Shin HW, Ye BS, Kim J, Kim SM, Sohn YH. The contribution of a spinal
mechanism in developing peripheral myoclonus: a case report. Mov Disord.
2007;22:1350–2.
13. Martinez MS, Fontoira M, Celester G, Castro del Rio M, Permuy J, Iglesias A.
Myoclonus of peripheral origin: case secondary to a digital nerve lesion.
Mov Disord. 2001;16:970–4.
14. Levy R, Plassche W, Riggs J, Shoulson I. Spinal myoclonus related to an
arteriovenous malformation. Response to clonazepam therapy. Arch Neurol.
1983;40:254–5.
15. Casazza M, Bracchi M, Girotti F. Spinal myoclonus and clinical worsening
after intravenous contrast medium in a patient with spinal arteriovenous
malformation. AJNR Am J Neuroradiol. 1985;6:965–6.
16. Berger JR, Bender A, Resnick L, Perlmutter D. Spinal myoclonus associated
with HTLV III/LAV infection. Arch Neurol. 1986;43:1203–4.
17. Dhaliwal GS, McGreal DA. Spinal myoclonus in association with herpes
zoster infection: two case reports. Can J Neurol Sci. 1974;1:239–41.
18. Bhatia K, Thompson PD, Marsden CD. “Isolated” postinfectious myoclonus.
J Neurol Neurosurg Psychiatry. 1992;55:1089–91.
19. Alroughani RA, Ahmed SF, Khan RA, Al-Hashel JY. Spinal segmental myoclonus
as an unusual presentation of multiple sclerosis. BMC Neurol. 2015;15:15.
20. Kobayashi J, Yokochi F, Takasu M, Tobisawa S, Shimizu T. Spinal segmental
myoclonus during postural maintenance in a patient with cervical
spondylosis: a case report. Intern Med. 2011;50:1839–41.
21. Hoehn MM, Cherington M. Spinal myoclonus. Neurology. 1977;27:942–6.
22. Roobol TH, Kazzaz BA, Vecht CJ. Segmental rigidity and spinal myoclonus as
a paraneoplastic syndrome. J Neurol Neurosurg Psychiatry. 1987;50:628–31.
23. Allen NM, Moran MM, King MD. Not all twitching is epileptic! Hand
myoclonus in a boy with spinal cord tumor. J Pediatr. 2013;162:431. e431.
24. Massimi L, Battaglia D, Paternoster G, Martinelli D, Sturiale C, Di Rocco C.
Segmental spinal myoclonus and metastatic cervical ganglioglioma: an
unusual association. J Child Neurol. 2009;24:365–9.
25. Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic
study. Arch Neurol. 1986;43:1025–31.
26. Agarwal P, Frucht SJ. Myoclonus. Curr Opin Neurol. 2003;16:515–21.
27. Keswani SC, Kossoff EH, Krauss GL, Hagerty C. Amelioration of spinal
myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry. 2002;73:457–8.
28. van der Salm SM, Erro R, Cordivari C, Edwards MJ, Koelman JH, van den
Ende T, et al. Propriospinal myoclonus: clinical reappraisal and review of
literature. Neurology. 2014;83:1862–70.
29. van der Salm SM, Koelman JH, Henneke S, van Rootselaar AF, Tijssen MA.
Axial jerks: a clinical spectrum ranging from propriospinal to psychogenic
myoclonus. J Neurol. 2010;257:1349–55.
30. Esposito M, Erro R, Edwards MJ, Cawley N, Choi D, Bhatia KP, et al.
The pathophysiology of symptomatic propriospinal myoclonus. Mov
Disord. 2014;29:1097–9.
31. Erro R, Edwards MJ, Bhatia KP, Esposito M, Farmer SF, Cordivari C.
Psychogenic axial myoclonus: clinical features and long-term outcome.
Parkinsonism Relat Disord. 2014;20:596–9.
32. Erro R, Bhatia KP, Edwards MJ, Farmer SF, Cordivari C. Clinical diagnosis
of propriospinal myoclonus is unreliable: an electrophysiologic study.
Mov Disord. 2013;28:1868–73.
33. Roze E, Bounolleau P, Ducreux D, Cochen V, Leu-Semenescu S, Beaugendre
Y, et al. Propriospinal myoclonus revisited: Clinical, neurophysiologic, and
neuroradiologic findings. Neurology. 2009;72:1301–9.
34. Heilman KM. Orthostatic tremor. Arch Neurol. 1984;41:880–1.
35. Brown P. New clinical sign for orthostatic tremor. Lancet. 1995;346:306–7.
36. Thompson PD, Rothwell JC, Day BL, Berardelli A, Dick JP, Kachi T, et al.
The physiology of orthostatic tremor. Arch Neurol. 1986;43:584–7.
37. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder
Society on Tremor. Ad Hoc Scientific Committee. Mov Disord.
1998;13(3):2–23.
38. Fung VS, Sauner D, Day BL. A dissociation between subjective and objective
unsteadiness in primary orthostatic tremor. Brain. 2001;124:322–30.
39. Gerschlager W, Brown P. Orthostatic tremor - a review. Handb Clin Neurol.
2011;100:457–62.
40. Boroojerdi B, Ferbert A, Foltys H, Kosinski CM, Noth J, Schwarz M. Evidence
for a non-orthostatic origin of orthostatic tremor. J Neurol Neurosurg
Psychiatry. 1999;66:284–8.
41. van Gerpen JA. A retrospective study of the clinical and electrophysiological
characteristics of 32 patients with orthostatic myoclonus. Parkinsonism Relat
Disord. 2014;20:889–93.
Termsarasab et al. Journal of Clinical Movement Disorders  (2015) 2:18 Page 11 of 13
42. Glass GA, Ahlskog JE, Matsumoto JY. Orthostatic myoclonus: a contributor
to gait decline in selected elderly. Neurology. 2007;68:1826–30.
43. Benito-Leon J, Rodriguez J, Orti-Pareja M, Ayuso-Peralta L, Jimenez-Jimenez
FJ, Molina JA. Symptomatic orthostatic tremor in pontine lesions.
Neurology. 1997;49:1439–41.
44. Lee HM, Kwon DY, Park MH, Koh SB, Kim SH. Symptomatic orthostatic
tremor with progressive cognitive impairment in spinal cord lesions.
Clin Neurol Neurosurg. 2012;114:1329–31.
45. Setta F, Manto MU. Orthostatic tremor associated with a pontine lesion or
cerebellar disease. Neurology. 1998;51:923.
46. Gerschlager W, Munchau A, Katzenschlager R, Brown P, Rothwell JC, Quinn
N, et al. Natural history and syndromic associations of orthostatic tremor: a
review of 41 patients. Mov Disord. 2004;19:788–95.
47. Gabellini AS, Martinelli P, Gulli MR, Ambrosetto G, Ciucci G, Lugaresi E. Orthostatic
tremor: essential and symptomatic cases. Acta Neurol Scand. 1990;81:113–7.
48. Ganos C, Maugest L, Apartis E, Gasca-Salas C, Caceres-Redondo MT, Erro R,
et al. The long-term outcome of orthostatic tremor. J Neurol Neurosurg
Psychiatry. 2015.
49. Wills AJ, Brusa L, Wang HC, Brown P, Marsden CD. Levodopa may improve
orthostatic tremor: case report and trial of treatment. J Neurol Neurosurg
Psychiatry. 1999;66:681–4.
50. Hellriegel H, Raethjen J, Deuschl G, Volkmann J. Levetiracetam in primary
orthostatic tremor: a double-blind placebo-controlled crossover study. Mov
Disord. 2011;26:2431–4.
51. Wu YR, Ashby P, Lang AE. Orthostatic tremor arises from an oscillator in the
posterior fossa. Mov Disord. 2001;16:272–9.
52. Muthuraman M, Hellriegel H, Paschen S, Hofschulte F, Reese R, Volkmann J,
et al. The central oscillatory network of orthostatic tremor. Mov Disord.
2013;28:1424–30.
53. Guridi J, Rodriguez-Oroz MC, Arbizu J, Alegre M, Prieto E, Landecho I, et al.
Successful thalamic deep brain stimulation for orthostatic tremor. Mov
Disord. 2008;23:1808–11.
54. Norton JA, Wood DE, Day BL. Is the spinal cord the generator of 16-Hz
orthostatic tremor? Neurology. 2004;62:632–4.
55. Feil K, Bottcher N, Guri F, Krafczyk S, Schoberl F, Zwergal A, et al. Long-term
course of orthostatic tremor in serial posturographic measurement.
Parkinsonism Relat Disord. 2015;21:905–10.
56. Krauss JK, Weigel R, Blahak C, Bazner H, Capelle HH, Grips E, et al. Chronic
spinal cord stimulation in medically intractable orthostatic tremor. J Neurol
Neurosurg Psychiatry. 2006;77:1013–6.
57. Gasca-Salas C, Arcocha J, Artieda J, Pastor P. Orthostatic myoclonus: an
underrecognized cause of unsteadiness? Parkinsonism Relat Disord. 2013;19:1013–7.
58. Leu-Semenescu S, Roze E, Vidailhet M, Legrand AP, Trocello JM, Cochen V,
et al. Myoclonus or tremor in orthostatism: an under-recognized cause of
unsteadiness in Parkinson’s disease. Mov Disord. 2007;22:2063–9.
59. Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 2002;
17:726–34.
60. Thomas R, Behari M, Gaikwad SB, Prasad K. An unusual case of paroxysmal
kinesigenic dyskinesia. J Clin Neurosci. 2002;9:94–7.
61. Prashantha DK, Pal PK. Pseudohypoparathyroidism manifesting with
paroxysmal dyskinesias and seizures. Mov Disord. 2009;24:623–4.
62. Dure LS, Mussell HG. Paroxysmal dyskinesia in a patient with
pseudohypoparathyroidism. Mov Disord. 1998;13:746–8.
63. Norlinah MI, Shahizon AM. Paroxysmal dyskinesia as an unusual and only
presentation of subcortical white matter ischaemia: a report of two cases.
Med J Malaysia. 2008;63:410–2.
64. Marrufo M, Politsky J, Mehta S, Morgan JC, Sethi KD. Paroxysmal Kinesigenic
Segmental Myoclonus due to a spinal cord glioma. Mov Disord. 2007;22:1801–3.
65. Yulug B, Bakar M, Ozer HH, Yilmaz M, Unlu B. Paroxysmal kinesigenic
dyskinesia and cervical disc prolapse with cord compression: more than a
coincidence? J Neuropsychiatry Clin Neurosci. 2008;20:237–9.
66. Cosentino C, Torres L, Flores M, Cuba JM. Paroxysmal kinesigenic dystonia
and spinal cord lesion. Mov Disord. 1996;11:453–5.
67. Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain.
1975;98:189–202.
68. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple
sclerosis. Mov Disord. 1995;10:418–23.
69. Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol
Neurosurg Psychiatry. 1975;38:617–23.
70. Twomey JA, Espir ML. Paroxysmal symptoms as the first manifestations of
multiple sclerosis. J Neurol Neurosurg Psychiatry. 1980;43:296–304.
71. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of
painful tonic spasms in multiple sclerosis. Mov Disord. 1999;14:331–5.
72. Burguera JA, Catala J, Casanova B. Thalamic demyelination and
paroxysmal dystonia in multiple sclerosis. Mov Disord. 1991;6:379–81.
73. Zenzola A, De Mari M, De Blasi R, Carella A, Lamberti P. Paroxysmal dystonia
with thalamic lesion in multiple sclerosis. Neurol Sci. 2001;22:391–4.
74. Waubant E, Alize P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in
multiple sclerosis. Neurology. 2001;57:2320–1.
75. Honig LS, Wasserstein PH, Adornato BT. Tonic spasms in multiple sclerosis.
Anatomic basis and treatment. West J Med. 1991;154:723–6.
76. Striano P, Striano S, Carrieri PB, Boccella P. Epilepsia partialis continua as a
first symptom of multiple sclerosis: electrophysiological study of one case.
Mult Scler. 2003;9:199–203.
77. Sokic DV, Stojsavljevic N, Drulovic J, Dujmovic I, Mesaros S, Ercegovac M,
et al. Seizures in multiple sclerosis. Epilepsia. 2001;42:72–9.
78. Usmani N, Bedi G, Lam BL, Sheremata WA. Association between
paroxysmal tonic spasms and neuromyelitis optica. Arch Neurol. 2012;
69:121–4.
79. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in
neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics.
Arch Neurol. 2012;69:1026–31.
80. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM,
Takahashi T, et al. Distinction between MOG antibody-positive and
AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;
82:474–81.
81. Sghirlanzoni A, Pareyson D. Carbamazepine for paroxysmal dystonia due to
spinal cord lesions. Ital J Neurol Sci. 1993;14:187.
82. Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide
of brain-stem and spinal paroxysmal disturbances in multiple sclerosis.
J Neurol Neurosurg Psychiatry. 1975;38:191–3.
83. Solaro C, Lunardi GL, Capello E, Inglese M, Messmer Uccelli M, Uccelli A,
et al. An open-label trial of gabapentin treatment of paroxysmal symptoms
in multiple sclerosis patients. Neurology. 1998;51:609–11.
84. Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov
Disord. 1991;6:12–20.
85. Meinck HM, Thompson PD. Stiff man syndrome and related conditions.
Mov Disord. 2002;17:853–66.
86. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to
GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.
N Engl J Med. 1990;322:1555–60.
87. Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E, et al.
Autoantibodies to glutamic acid decarboxylase in three patients with
cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and
polyendocrine autoimmunity. Neurology. 1997;49:1026–30.
88. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, et al.
Autoantibodies to a 128-kd synaptic protein in three women with the stiff-
man syndrome and breast cancer. N Engl J Med. 1993;328:546–51.
89. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune
disease. Curr Opin Neurol. 2011;24:346–53.
90. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL,
et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann
Neurol. 2005;58:96–107.
91. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog
JE, et al. Stiff-man syndrome and variants: clinical course, treatments, and
outcomes. Arch Neurol. 2012;69:230–8.
92. Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, et al.
Paraneoplastic stiff-person syndrome: passive transfer to rats by means
of IgG antibodies to amphiphysin. Lancet. 2005;365:1406–11.
93. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin
antibodies: distinctive features of a rare disease. Neurology. 2008;71:1955–8.
94. Raju R, Rakocevic G, Chen Z, Hoehn G, Semino-Mora C, Shi W, et al.
Autoimmunity to GABAA-receptor-associated protein in stiff-person
syndrome. Brain. 2006;129:3270–6.
95. Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-
person syndrome and other GAD-positive CNS disorders. Neurology. 2013;
81:1962–4.
96. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ,
McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man
syndrome phenotype. JAMA Neurol. 2013;70:44–50.
97. Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: insights into a complex
autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015;86:840–8.
Termsarasab et al. Journal of Clinical Movement Disorders  (2015) 2:18 Page 12 of 13
98. Floeter MK, Valls-Sole J, Toro C, Jacobowitz D, Hallett M. Physiologic studies
of spinal inhibitory circuits in patients with stiff-person syndrome.
Neurology. 1998;51:85–93.
99. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid
changes in stiff-person syndrome. Arch Neurol. 2005;62:970–4.
100. Kim MJ, Lim YM, Kim JS, Kim KK. GABAergic changes in (11)C-flumazenil PET
in the drug-naive Stiff-Person syndrome. Can J Neurol Sci. 2013;40:91–3.
101. Perani D, Garibotto V, Panzacchi A, Moresco RM, Ortelli P, Corbo M, et al.
PET evidence of central GABAergic changes in stiff-person syndrome. Mov
Disord. 2007;22:1030–3.
102. Khasani S, Becker K, Meinck HM. Hyperekplexia and stiff-man syndrome:
abnormal brainstem reflexes suggest a physiological relationship. J Neurol
Neurosurg Psychiatry. 2004;75:1265–9.
103. Ughratdar I, Sivakumar G, Basu S. Spinal cord stimulation to abort
painful spasms of atypical stiff limb syndrome. Stereotact Funct
Neurosurg. 2010;88:183–6.
104. Whiteley AM, Swash M, Urich H. Progressive encephalomyelitis with rigidity.
Brain. 1976;99:27–42.
105. Howell DA, Lees AJ, Toghill PJ. Spinal internuncial neurones in
progressive encephalomyelitis with rigidity. J Neurol Neurosurg
Psychiatry. 1979;42:773–85.
106. Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B,
et al. Glycine receptor antibodies in PERM and related syndromes:
characteristics, clinical features and outcomes. Brain. 2014;137:2178–92.
107. Leigh PN, Rothwell JC, Traub M, Marsden CD. A patient with reflex
myoclonus and muscle rigidity: “jerking stiff-man syndrome”. J Neurol
Neurosurg Psychiatry. 1980;43:1125–31.
108. Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blocker IM, et al.
Progressive encephalomyelitis with rigidity and myoclonus: a new variant
with DPPX antibodies. Neurology. 2014;82:1521–8.
109. Back T, Stoltenburg-Didinger G, Ploner CJ, Meisel H, Zschenderlein R. A new
variant of progressive encephalomyelitis with rigidity associated with
cerebellar ataxia and dementia: correlation of MRI and histopathological
changes. A case report. Neurol Res. 1997;19:187–91.
110. Shugaiv E, Leite MI, Sehitoglu E, Woodhall M, Cavus F, Waters P, et al.
Progressive encephalomyelitis with rigidity and myoclonus: a syndrome with
diverse clinical features and antibody responses. Eur Neurol. 2013;69:257–62.
111. Turner MR, Irani SR, Leite MI, Nithi K, Vincent A, Ansorge O. Progressive
encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor
antibodies. Neurology. 2011;77:439–43.
112. Stern WM, Howard R, Chalmers RM, Woodhall MR, Waters P, Vincent A, et al.
Glycine receptor antibody mediated Progressive Encephalomyelitis with
Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome.
Pract Neurol. 2014;14:123–7.
113. Meinck HM, Faber L, Morgenthaler N, Seissler J, Maile S, Butler M, et al.
Antibodies against glutamic acid decarboxylase: prevalence in neurological
diseases. J Neurol Neurosurg Psychiatry. 2001;71:100–3.
114. Schmidt C, Freilinger T, Lieb M, Remi J, Klein M, Straube A, et al. Progressive
encephalomyelitis with rigidity and myoclonus preceding otherwise
asymptomatic Hodgkin’s lymphoma. J Neurol Sci. 2010;291:118–20.
115. Spitz M, Ferraz HB, Barsottini OG, Gabbai AA. Progressive encephalomyelitis
with rigidity: a paraneoplastic presentation of oat cell carcinoma of the
lung. Case report. Arq Neuropsiquiatr. 2004;62:547–9.
116. Jain S, DeGeorgia M. Brain death-associated reflexes and automatisms.
Neurocrit Care. 2005;3:122–6.
117. Spittler JF, Wortmann D, von During M, Gehlen W. Phenomenological
diversity of spinal reflexes in brain death. Eur J Neurol. 2000;7:315–21.
118. Saposnik G, Maurino J, Bueri J. Movements in brain death. Eur J Neurol.
2001;8:209–13.
119. Friedman AJ. Sympathetic response and brain death. Arch Neurol. 1984;41:15.
120. Beckmann Y, Ciftci Y, Incesu TK, Secil Y, Akhan G. Spinal reflexes in brain
death. Acta Neurol Belg. 2014;114:303–6.
121. McNair NL, Meador KJ. The undulating toe flexion sign in brain death. Mov
Disord. 1992;7:345–7.
122. Bueri JA, Saposnik G, Maurino J, Saizar R, Garretto NS. Lazarus’ sign in brain
death. Mov Disord. 2000;15:583–6.
123. Heytens L, Verlooy J, Gheuens J, Bossaert L. Lazarus sign and extensor
posturing in a brain-dead patient. Case report. J Neurosurg. 1989;71:449–51.
124. Hanna JP, Frank JI. Automatic stepping in the pontomedullary stage of
central herniation. Neurology. 1995;45:985–6.
125. Funakawa I, Mano Y, Takayanagi T. Painful hand and moving fingers. A case
report. J Neurol. 1987;234:342–3.
126. Wider C, Kuntzer T, Olivier P, Debatisse D, Nancoz R, Maeder P, et al. Painful
hand and moving finger treated by wearing a glove. Neurology. 2006;67:491–3.
127. Dressler D, Thompson PD, Gledhill RF, Marsden CD. The syndrome of
painful legs and moving toes. Mov Disord. 1994;9:13–21.
128. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG.
Case series of painful legs and moving toes: clinical and electrophysiologic
observations. Mov Disord. 2008;23:2062–6.
129. Takahashi H, Saitoh C, Iwata O, Nanbu T, Takada S, Morita S. Epidural spinal
cord stimulation for the treatment of painful legs and moving toes
syndrome. Pain. 2002;96:343–5.
130. Bermejo PE, Zabala JA. “Painless legs and moving toes” syndrome due to
spinal cord compression. Eur Spine J. 2008;17 Suppl 2:S294–5.
131. Nathan PW. Painful legs and moving toes: evidence on the site of the
lesion. J Neurol Neurosurg Psychiatry. 1978;41:934–9.
132. Schott GD. “Painful legs and moving toes”: the role of trauma. J Neurol
Neurosurg Psychiatry. 1981;44:344–6.
133. Azzi J, Atweh S, Saade N, Jabbour R. Neuroleptics as a cause of painful legs
and moving toes syndrome. BMJ Case Rep. 2014;2014.
134. Reich SG. Painful legs and moving toes. Handb Clin Neurol. 2011;100:375–83.
135. Guieu R, Sampieri F, Pouget J, Guy B, Rochat H. Adenosine in painful legs
and moving toes syndrome. Clin Neuropharmacol. 1994;17:460–9.
136. Drummond PD, Finch PM. Sympathetic nervous system involvement in the
syndrome of painful legs and moving toes. Clin J Pain. 2004;20:370–4.
137. Okuda Y, Suzuki K, Kitajima T, Masuda R, Asai T. Lumbar epidural block for
‘painful legs and moving toes’ syndrome: a report of three cases. Pain.
1998;78:145–7.
138. Guieu R, Tardy-Gervet MF, Blin O, Pouget J. Pain relief achieved by
transcutaneous electrical nerve stimulation and/or vibratory stimulation in a
case of painful legs and moving toes. Pain. 1990;42:43–8.
139. Eisa M, Singer C, Sengun C, Russel A, Jabbari B, Papapetropoulos S.
Treatment of painful limbs/moving extremities with botulinum toxin type A
injections. Eur Neurol. 2008;60:104–6.
140. Schoffer K. Painful leg moving toes treated with botulinum toxin type A: a
video report. Mov Disord. 2010;25:784–5.
141. Rodriguez RL, Fernandez HH. Sustained benefit of painful legs moving toes
syndrome with botulinum toxin type A. J Clin Neurosci. 2013;20:1031–2.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Termsarasab et al. Journal of Clinical Movement Disorders  (2015) 2:18 Page 13 of 13
